Advertisement
Screener

Silence Therapeutics plc (SLN) Increase (Decrease) in Other Current Assets

2.8 / 5 stars · 68/120 Roast Me

Silence Therapeutics plc Increase (Decrease) in Other Current Assets

Silence Therapeutics plc (SLN) reported Increase (Decrease) in Other Current Assets of $1.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-10

  • Silence Therapeutics plc increase (decrease) in other current assets for the quarter ending 2026-06-30 was $2.33M.
  • Silence Therapeutics plc increase (decrease) in other current assets for the quarter ending 2026-03-31 was -$931.00K, a 257.26% decline year-over-year.
  • Silence Therapeutics plc increase (decrease) in other current assets for the quarter ending 2025-12-31 was $1.74M.
  • Silence Therapeutics plc increase (decrease) in other current assets for the quarter ending 2025-09-30 was -$5.33M.
  • Silence Therapeutics plc increase (decrease) in other current assets for fiscal 2025 was -$6.02M, a 552.33% decline from fiscal 2024.
  • Silence Therapeutics plc increase (decrease) in other current assets for fiscal 2024 was $1.33M.
  • Silence Therapeutics plc increase (decrease) in other current assets for fiscal 2023 was -$1.96M, a 137.60% decline from fiscal 2022.
  • Silence Therapeutics plc increase (decrease) in other current assets for fiscal 2022 was $5.20M.
Period endIncrease (Decrease) in Other Current Assets 3 monthIncrease (Decrease) in Other Current Assets 6 monthIncrease (Decrease) in Other Current Assets 9 monthIncrease (Decrease) in Other Current Assets 12 month
2026-06-30$2.33M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
$1.40M
10-Q · filed 2026-08-10
$3.14M
derived: sum of 3 quarters · filed 2026-08-10
-$2.19M
derived: sum of 4 quarters · filed 2026-08-10
2026-03-31-$931.00K
10-Q · filed 2026-05-07
$810.00K
derived: sum of 2 quarters · filed 2026-05-07
-$4.52M
derived: sum of 3 quarters · filed 2026-05-07
-$7.54M
derived: sum of 4 quarters · filed 2026-08-10
2025-12-31$1.74M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$3.59M
derived: sum of 2 quarters · filed 2026-03-05
-$6.61M
derived: sum of 3 quarters · filed 2026-08-10
-$6.02M
10-K · filed 2026-03-05
2025-09-30-$5.33M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
-$8.35M
derived: sum of 2 quarters · filed 2026-08-10
-$7.76M
10-Q · filed 2025-11-06
-$8.15M
derived: sum of 4 quarters · filed 2026-08-10
2025-06-30-$3.02M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10
-$2.43M
10-Q · filed 2026-08-10
-$2.82M
derived: sum of 3 quarters · filed 2026-08-10
-$3.73M
derived: sum of 4 quarters · filed 2026-08-10
2025-03-31$592.00K
10-Q · filed 2026-05-07
$200.00K
derived: sum of 2 quarters · filed 2026-05-07
-$717.00K
derived: sum of 3 quarters · filed 2026-05-07
$1.15M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31-$392.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05
-$1.31M
derived: sum of 2 quarters · filed 2026-03-05
$562.00K
derived: sum of 3 quarters · filed 2026-03-05
$1.33M
10-K · filed 2026-03-05
2024-09-30-$917.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06
$954.00K
derived: sum of 2 quarters · filed 2025-11-06
$1.72M
10-Q · filed 2025-11-06
2024-06-30$1.87M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$2.64M
10-Q · filed 2025-08-07
2024-03-31$768.00K
10-Q · filed 2025-05-08
2023-12-31-$1.96M
10-K · filed 2025-02-27
2022-12-31$5.20M
10-K · filed 2025-02-27